Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide for HIV-Associated Kaposi's Sarcoma
NCT00019123Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 1996
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in Kaposi sarcoma (KS), sponsored by National Cancer Institute. Primary endpoint: Antitumor Activity (Regression or Stabilization) at 6 months. Started Apr 1996; status: completed.
02
Drugs
thalidomide
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on NCT00019123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00019123.